DV
Dividend Vision

STLN — Starling Oncology, Inc.

Starling Oncology, Inc. (STLN)

Starling Oncology is a biopharmaceutical company focused on the development of cancer therapies. The company does not currently distribute dividends to shareholders. This security is oriented toward growth-focused investors rather than those seeking current income.

STLN key facts

Asset type
Stock
Asset class
Equity
Inception date
06/04/2020
Last close
$6.45
Average volume
1086300.0